Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | CASP1 | P29466 | 2/20 | 0.32 |
| ▸ | CASP7 | P55210 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493251 | 0.81 | ALDH1A1 (0.50) | ADORA2AADORA2BKDM4EALDH1A1TSHR | |
| SCHEMBL6500772 | 0.77 | ADORA2A (0.35) | ADORA2AADORA2BSPRKDM4EALDH1A1 | |
| SCHEMBL23357465 | 0.73 | MAPT (0.36) | POLBKDM4EALDH1A1HSD17B10GAA | |
| SCHEMBL30711998 | 0.73 | MAPT (0.36) | POLBKDM4EALDH1A1HSD17B10GAA | |
| SCHEMBL5961519 | 0.72 | RCE1 (0.48) | ADORA2AADORA2BSPRPOLBKDM4E | |
| SCHEMBL7081776 | 0.72 | CCR2 (0.44) | ADORA2AADORA2BPOLBKDM4EALDH1A1 | |
| SCHEMBL6503506 | 0.71 | PDE10A (0.38) | KDM4EALDH1A1TSHRHSD17B10L3MBTL1 | |
| SCHEMBL19230707 | 0.70 | ADORA2A (0.44) | ADORA2AADORA2BSPRPOLBKDM4E | |
| SCHEMBL2176229 | 0.70 | KDM4E (0.40) | KDM4EALDH1A1TSHRHSD17B10L3MBTL1 | |
| SCHEMBL29904870 | 0.70 | KDM4E (0.40) | KDM4EALDH1A1TSHRHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992086-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-6962926-B2 | Antagonist of MCP-1 function, and compositions and methods of use thereof | TELIK, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040198719-A1 | Antagonist of MCP-1 function, and compositions and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
| US-20040077680-A1 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. | 2004-04-22 | — | — | US | disclosed |
| US-6670364-B2 | For example (1,3-dimethylpyrazolo(5,4-b)pyridin-5-yl)-N-(((4-fluorophenyl) amino)carbonyl)-carboxamide; useful in prevention or treatment of chronic or acute inflammatory or autoimmune diseases | TELIK, INC. | 2003-12-30 | — | — | US | disclosed |
| EP-1358188-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| WO-2002060900-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077680-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | ADORA2A 842/4885ADORA2B 1291/4885SPR 430/4885 |
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | ADORA2A 842/4885ADORA2B 1291/4885SPR 430/4885 |
| US-20040198719-A1 | Antagonist of MCP-1 function, and compositions and methods of use thereof | CCR1, CCL11, CCL2 | ADORA2A 631/4885ADORA2B 394/4885SPR 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.